Pilot Study of the Predictive Value of TREM1 Expression and Activation in Inflammation and Radio-induced Mammary Fibrosis (TREM-1)
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Studietype
Studietype
Registrering (Forventet)
Registrering
Fase
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
-
Metz, Frankrike
- Rekruttering
- Centre Hospitalier de Metz Thionville
-
Ta kontakt med:
- Claire Gamelon - Benichou, MD
-
Nancy, Frankrike
- Rekruttering
- Institut de Cancérologie de Lorraine
-
-
-
-
SUD
-
Esch-sur-Alzette, SUD, Luxembourg, 4240
- Rekruttering
- Centre François Baclesse
-
Ta kontakt med:
- Guillaume Vogin, MD PhD
-
Ta kontakt med:
- Charlotte Lieunard
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Group A
- Patients over 18 years old,
- Breast cancer (adenocarcinoma in situ or invasive)
- Non-metastatic disease
- Radiotherapy after conservative surgery with irradiation of the breast alone and complement on the operating bed (optional) completed two to six months ago
- Absence of postoperative complications
- Early radio-induced epidermis grade ≥2 (CTCAE v4.0) persistent at inclusion
- Chest circumference <120 cm and Cup <E,
- Absence of breast reconstructive surgery,
- Signature of informed consent,
- Affiliation to a social security scheme for French patients.
Group B
- Patients over 18 years old,
- Breast cancer (adenocarcinoma in situ or invasive)
- Non-metastatic disease
- Radiotherapy after conservative surgery with irradiation of the breast alone and complement on the operating bed (optional), completed two to six months ago
- Absence of postoperative complications
- Early grade 0-1 radiation-induced epidermis (CTCAE v4.0) at inclusion
- Chest circumference <120 cm and Cup <E,
- Absence of breast reconstructive surgery,
- Signature of informed consent,
- Affiliation to a social security scheme for French patients.
Groups C, D
Patients included in the SPLICIRAD study who have formulated their agreement for the use of supernumerary samples at the time of inclusion:
- 10 patients with late pathologic radio-induced fibrosis (more than 6 months after the end of radiotherapy), grade CTCAE v4.0 ≥ 3 vs.
- 10 patients without late pathological radio-induced fibrosis of grade CTCAE v4.0 ≤ 1 (follow-up after RT ≥4 years)
Group E Patients over 18 who have given their consent to the Blood Establishment for the use of their samples for research purposes.
Non-inclusion criteria for groups A, B, C, D:
- Systemic inflammatory disease associated with individual radiosensitivity
- Dermatological pathology in the breast
- Radiotherapy having delivered an overdose> 107% of the prescribed dose in at least 10% of the PTV
- Diabetes
- Active smoking
- Chronic systemic anti-inflammatory therapy, immunotherapy, immunosuppressants, anti-TNF
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Annen
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Annen: Group A
Patients with early grade ≥2 radio-induced epidermis Intervention : blood sample
|
Blood sample of 7 mL whole venous blood in an EDTA citrate tube (4.5 mL) and a PAXgene Blood RNA tube (2.5 mL).
|
|
Annen: Group B
Patients with early grade 0-1 radiation-induced epidermis Intervention : blood sample
|
Blood sample of 7 mL whole venous blood in an EDTA citrate tube (4.5 mL) and a PAXgene Blood RNA tube (2.5 mL).
|
|
Ingen inngripen: Group C
Patients with late pathologic radio-induced fibrosis (more than 6 months after the end of radiotherapy), grade CTCAE v4.0 ≥ 3 No intervention : Blood sample already collected from another study and patients agree to use their blood sample for another research
|
|
|
Ingen inngripen: Group D
Patients without late pathologic radio-induced fibrosis of grade CTCAE v4.0 ≤ 1 (follow-up after RT ≥4 years) No intervention : Blood sample already collected from another study and patients agree to use their blood sample for another research
|
|
|
Ingen inngripen: Group E
Control group : patients over 18 who have given their consent to the Blood Establishment for the use of their samples for research purposes.
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Coorelate the amount of circulating TREM1 with the presence or absence of early persistent radiation-induced epidermis.
Tidsramme: after recruitment of all samples, an average of 2 years
|
Correlate the amount of circulating TREM1 with the presence or absence of early persistent radiation-induced epidermis.
|
after recruitment of all samples, an average of 2 years
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Correlate the amount of circulating TREM1 with the presence or absence of late radio-induced fibrosis / atrophy
Tidsramme: after recruitment of all samples, an average of 2 years
|
Correlate the amount of circulating TREM1 with the presence or absence of late radio-induced fibrosis / atrophy
|
after recruitment of all samples, an average of 2 years
|
|
Intrinsic characteristics of the TREM1 blood assay in ELISA technique
Tidsramme: after recruitment of all samples, an average of 2 years
|
Intrinsic characteristics of the TREM1 blood assay in ELISA technique
|
after recruitment of all samples, an average of 2 years
|
|
correlate TREM-1 expression with circulating markers of inflammation such as IL-6, CRP, and fibrosis such as TGF-beta, IL-1beta, TNF-alpha
Tidsramme: after recruitment of all samples, an average of 2 years
|
correlate TREM-1 expression with circulating markers of inflammation such as IL-6, CRP, and fibrosis such as TGF-beta, IL-1beta, TNF-alpha
|
after recruitment of all samples, an average of 2 years
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Samarbeidspartnere
Samarbeidspartnere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Forventet)
Primær fullføring
Studiet fullført (Forventet)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- TREM-1
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .